CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo

Journal of Immunology

Volumn 170, Issue 3, 2003, Pages 1510-1516

  Tang, Qizhi ^a   Smith, Judy A ^b   Szot, Greg L ^a   Zhou, Ping ^c   Alegre, Maria Luisa ^c   Henriksen, Kammi J ^a   Thompson, Craig B ^d   Bluestone, Jeffrey A ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; FC RECEPTOR; MONOCLONAL ANTIBODY CD3; PROTEIN BCL XL;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL ISOLATION; CLONAL ANERGY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENE CONTROL; GRAFT SURVIVAL; HEART GRAFT; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; WILD TYPE;

EID: 0037310650     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.3.1510     Document Type: Article

References (45)

1. Thistlethwaite, J. R., Jr., A. B. Cosimi, F. L. Delmonico, R. H. Rubin, N. Talkoff-Rubin, P. W. Nelson, L. Fang. and P. S. Russell. 1984. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation 38:695.
2. Chatenoud, L., J. Primo, and J. F. Bach. 1997. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158:2947.
3. Chatenoud, L., E. Thervet, J. Primo, and J. F. Bach. 1994. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 91:123.
4. Hirsch, R., M. Eckhaus, H. Auchincloss, Jr., D. H. Sachs, and J. A. Bluestone. 1988. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J. Immunol. 140:3766.
5. Lenardo, M., K. M. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang, and L. Zheng. 1999. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17:221.
6. Rathmell, J. C., and C. B. Thompson. 1999. The central effectors of cell death in the immune system. Annu. Rev. Immunol. 17:781.
7. L. Proc. Natl. Acad. Sci. USA 96:14871.
8. Van Parijs, L., A. Biuckians, and A. K. Abbas. 1998. Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J. Immunol. 160:2065.
9. Boise, L. H., P. J. Noel, and C. B. Thompson. 1995. CD28 and apoptosis. Curr. Opin. Immunol. 7:620.
10. Boussiotis, V. A., B. J. Lee, G. J. Freeman, J. G. Gribben, and L. M. Nadler. 1997. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J. Immunol. 159:3156.
11. Khoruts, A., A. Mondino, K. A. Pape, S. L. Reiner, and M. K. Jenkins. 1998. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J. Exp. Med. 187:225.
12. Walsh, P. T., and R. O'Connor. 2000. The insulin-like growth factor-I receptor is regulated by CD28 and protects activated T cells from apoptosis. Eur. J. Immunol. 30:1010.
13. short and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur. J. Immunol. 30:2765.
14. Hildeman, D. A., T. Mitchell, T. K. Teague, P. Henson, B. J. Day, J. Kappler, and P. C. Marrack. 1999. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 10:735.
15. Hildeman, D. A., Y. Zhu, T. C. Mitchell, P. Bouillet, A. Strasser, J. Kappler, and P. Marrack. 2002. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 16:759.
16. Vander Heiden, M. G., and C. B. Thompson. 1999. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat. Cell Biol. 1:E209.
17. Sperling, A. I., J. A. Auger, B. D. Ehst, I. C. Rulifson, C. B. Thompson, and J. A. Bluestone. 1996. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J. Immunol. 157:3909.
18. L. Immunity 3:87.
19. Schwartz, R. H. 1997. T cell clonal anergy. Curr. Opin. Immunol. 9:351.
20. Lane, P. 1995. Blocking CD28/B7 with soluble competitors: immunological phenotype of mCTLA4-Hγ1 transgenic mice. Res. Immunol. 146:176.
21. Perez, V. L., L. Van Parijs, A. Biuckians, X. X. Zheng, T. B. Strom, and A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411.
22. Lee, K. M., E. Chuang, M. Griffin, R. Khattri, D. K. Hong, W. Zhang, D. Straus, L. E. Samelson, C. B. Thompson, and J. A. Bluestone. 1998. Molecular basis of T cell inactivation by CTLA-4. Science 282:2263.
23. Greenwald, R. J., V. A. Boussiotis, R. B. Lorsbach, A. K. Abbas, and A. H. Sharpe. 2001. CTLA-4 regulates induction of anergy in vivo. Immunity 14:145.
24. Oosterwegel, M. A., D. A. Mandelbrot, S. D. Boyd, R. B. Lorsbach, D. Y. Jarrett, A. K. Abbas, and A. H. Sharpe. 1999. The role of CTLA-4 in regulating Th2 differentiation. J. Immunol. 163:2634.
25. Khattri, R., J. A. Auger, M. D. Griffin, A. H. Sharpe, and J. A. Bluestone. 1999. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J. Immunol. 162:5784.
26. Eagar, T. N., N. J. Karandikar, J. A. Bluestone, and S. D. Miller. 2002. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur. J. Immunol. 32:972.
27. Szot, G. L., P. Zhou, A. H. Sharpe, G. He, O. Kim, K. A. Newell, J. A. Bluestone, and J. R. Thistlethwaite, Jr. 2000. Absence of host B7 expression is sufficient for long-term murine vascularized heart allograft survival. Transplantation 69:904.
28. Singer, G. G., and A. K. Abbas. 1994, The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365.
29. + T cells responding to a bacterial superantigen. J. Immunol. 154:4302.
30. Mogil, R. J., L. Radvanyi, R. Gonzalez-Quintial, R. Miller, G. Mills, A. N. Theofilopoulos, and D. R. Green. 1995. Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int. Immunol. 7:1451.
31. Adachi, M., S. Suematsu, T. Suda, D. Watanabe, H. Fukuyama, J. Ogasawara, T. Tanaka, N. Yoshida, and S. Nagata. 1996. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc. Natl. Acad, Sci. USA 93:2131.
32. + T cells. J. Immunol. 163:2358.
33. Sytwu, H. K., R. S. Liblau, and H. O. McDevitt. 1996. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 5:17.
34. Zheng, L., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, and M. J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377:348.
35. Renno, T., M. Hahne, J. Tschopp, and H. R. MacDonald. 1996. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J. Exp. Med. 183:431.
36. Klausner, R. D., J. J. O'Shea, H. Luong, P. Ross, J. A. Bluestone, and L. E. Samelson. 1987. T cell receptor tyrosine phosphorylation: variable coupling for different activating ligands. J. Biol. Chem. 262:12654.
37. Mixter, P. F., J. Q. Russell, and R. C. Budd. 1994. Delayed kinetics of T lymphocyte anergy and deletion in lpr mice. J. Autoimmun. 7:697.
38. Scott, D. E., W. J. Kisch, and A. D. Steinberg. 1993. Studies of T cell deletion and T cell anergy following in vivo administration of SEB to normal and lupus-prone mice. J. Immunol. 150:664.
39. Mountz, J. D., H. Bluethmann, T. Zhou. and J. Wu. 1994. Defective clonal deletion and anergy induction in TCR transgenic lpr/lpr mice. Semin. Immunol. 6:27.
40. Wells, A. D., M. C. Walsh, J. A. Bluestone, and L. A. Turka. 2001. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J. Clin. Invest. 108:895.
41. kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 6:290.
42. Wells, A. D., X. C. Li, Y. Li, M. C. Walsh, X. X. Zheng, Z. Wu, G. Nunez, A. Tang, M. Sayegh, W. W. Hancock, T. B. Strom, and L. A. Turka. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5:1303.
43. Li, Y., X. C. Li, X. X. Zheng, A. D. Wells, L. A. Turka, and T. B. Strom. 1999. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5:1298.
44. Woodle, E. S., D. Xu, R. A. Zivin, J. Auger, J. Charette, R. O'Laughlin, D. Peace, L. K. Jollife, T. Haverty, J. A. Bluestone, and J. R. Thistlethwaite, Jr. 1999. Phase 1 trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68:608.
45. Herold, K. C., W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, and J. A. Bluestone. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346:1692.